346 related articles for article (PubMed ID: 30947287)
1. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells.
Willms A; Schittek H; Rahn S; Sosna J; Mert U; Adam D; Trauzold A
PLoS One; 2019; 14(4):e0214847. PubMed ID: 30947287
[TBL] [Abstract][Full Text] [Related]
2. Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways.
Lin FL; Hsu JL; Chou CH; Wu WJ; Chang CI; Liu HJ
Eur J Pharmacol; 2011 Jan; 650(1):120-9. PubMed ID: 20951126
[TBL] [Abstract][Full Text] [Related]
3. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax.
Gupta SC; Reuter S; Phromnoi K; Park B; Hema PS; Nair M; Aggarwal BB
J Biol Chem; 2011 Jan; 286(2):1134-46. PubMed ID: 21078664
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.
Liu X; Qiu F; Liu Z; Lan Y; Wang K; Zhou PK; Wang Y; Hua ZC
Apoptosis; 2014 Oct; 19(10):1532-44. PubMed ID: 25113506
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NFκβ pathways.
Harsha Raj M; Yashaswini B; Rössler J; Salimath BP
Apoptosis; 2016 May; 21(5):578-93. PubMed ID: 26921178
[TBL] [Abstract][Full Text] [Related]
6. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
7. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells.
Sano E; Kazaana A; Tadakuma H; Takei T; Yoshimura S; Hanashima Y; Ozawa Y; Yoshino A; Suzuki Y; Ueda T
Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119037. PubMed ID: 33839168
[TBL] [Abstract][Full Text] [Related]
9. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
10. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
12. Bax is essential for death receptor-mediated apoptosis in human colon cancer cells.
Zhu S; Li T; Tan J; Yan X; Zhang D; Zheng C; Chen Y; Xiang Z; Cui H
Cancer Biother Radiopharm; 2012 Nov; 27(9):577-81. PubMed ID: 23113596
[TBL] [Abstract][Full Text] [Related]
13. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
[TBL] [Abstract][Full Text] [Related]
15. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
17. TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression.
Clemons NJ; Anderson RL
Cell Stress Chaperones; 2006; 11(4):343-55. PubMed ID: 17278883
[TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
20. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells.
Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T
Cancer Lett; 2010 Jan; 287(1):98-108. PubMed ID: 19577358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
